Pharmacogenetic CYP2D6 variability, phenoconversion and treatment outcomes: A Danish population-based cohort study in 6,798 individuals initiating atomoxetine treatment

INTRODUCTION: Atomoxetine, a first-line treatment option for ADHD, is affected by pharmacogenetic (PGx) variation of the drug-metabolizing enzyme CYP2D6. Despite the recommendation of CYP2D6 testing, the use of PGx-guided dosing remains low in Denmark. OBJECTIVES: We investigated wide-ranging clinic...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishtiak-Ahmed, K., Lunenburg, C., Thirstrup, J., Clausen, L., Thomsen, P., Gasse, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2022
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9567364/
http://dx.doi.org/10.1192/j.eurpsy.2022.588

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9567364/
http://dx.doi.org/10.1192/j.eurpsy.2022.588

Ejemplares similares